Company profile
SELLAS Life Sciences Group, Inc.
NASDAQ: SLS · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
50DFH 65DQ 46GM 8SS 63
v0.1 · 65/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$26.9M
Employees
13
as of 2026-08-08
Market cap
$2.2B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$26.9M-$26.9M2025
Operating income-$28.3M-$28.3M2025
Total assets$78.3M$78.3M2025
Liabilities$7.5M$7.5M2025
Equity$70.9M$70.9M2025
Revenue trend
FY2013 – FY2023 · USD
FY13
FY13
FY14
FY20
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is SELLAS Life Sciences Group, Inc.’s revenue?
SELLAS Life Sciences Group, Inc. booked $0 in FY2023 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Denali Therapeutics Inc.52DViking Therapeutics, Inc.69BAmylyx Pharmaceuticals, Inc.51DRest Ez Inc.——Kardigan, Inc.——Cullinan Therapeutics, Inc.50DNeighbors
New York →Key facts
CEOAngelos Stergiou
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York, NY
ExchangeNASDAQ: SLS
Employees13
IPO date2008-03-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.